Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Calphostin C (HB0160)
Description:Potent, selective PKC inhibitor. Also antagonizes the Tcf/β-catenin complex
Purity:>95%
Camostat mesylate (HB3595)
Description:Serine protease inhibitor. Inhibits TMPRSS2 and partially blocks SARS-Cov2 entry in vitro.
Purity:>98%
cAMPS-Sp triethylammonium salt (HB0566)
Description:Potent, specific cAMP-dependent protein kinases activator. Cell-permeable.
Purity:>98%
CCG 1423 (HB3389)
Description:Rho/SRF pathway inhibitor. Induces intermediate mesoderm differentiation from ESCs.
Purity:>99%
CGP 37157 (HB1132)
Description:Potent, selective mitochondria Na+ / Ca2+ exchange inhibitor
Purity:>99%